Gilead Sciences, Inc. (NASDAQ: GILD) has a higher price-to-earnings ratio of 15.98x compared to its average ratio,, and the 36-month beta value for GILD is at 0.31. Analysts have varying views on the stock, with 14 analysts rating it as a “buy,” 2 rating it as “overweight,” 15 as “hold,” and 1 as “sell.”
The average price suggested by analysts for GILD is $89.82, which is $15.3 above the current market price. The public float for GILD is 1.25B, and currently, shorts hold a 1.57% of that float. The average trading volume for GILD on November 17, 2023 was 5.60M shares.
GILD) stock’s latest price update
Gilead Sciences, Inc. (NASDAQ: GILD)’s stock price has decreased by -0.69 compared to its previous closing price of 75.04. However, the company has seen a -0.61% decrease in its stock price over the last five trading sessions. Seeking Alpha reported 2023-11-15 that Gilead Sciences has a robust pipeline in oncology and HIV, indicating sustained growth potential. The company offers dividends, buybacks, and an attractive valuation, making it an appealing investment option. Gilead’s path to $100 per share is plausible with transformative catalysts and upcoming clinical data.
GILD’s Market Performance
Gilead Sciences, Inc. (GILD) has seen a -0.61% fall in stock performance for the week, with a -6.46% decline in the past month and a -1.79% plunge in the past quarter. The volatility ratio for the week is 1.87%, and the volatility levels for the past 30 days are at 1.97% for GILD. The simple moving average for the past 20 days is -4.46% for GILD’s stock, with a -5.56% simple moving average for the past 200 days.
Analysts’ Opinion of GILD
Many brokerage firms have already submitted their reports for GILD stocks, with Deutsche Bank repeating the rating for GILD by listing it as a “Hold.” The predicted price for GILD in the upcoming period, according to Deutsche Bank is $75 based on the research report published on November 09, 2023 of the current year 2023.
GILD Trading at -3.00% from the 50-Day Moving Average
After a stumble in the market that brought GILD to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -16.96% of loss for the given period.
Volatility was left at 1.97%, however, over the last 30 days, the volatility rate increased by 1.87%, as shares sank -5.00% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +0.78% upper at present.
During the last 5 trading sessions, GILD fell by -0.61%, which changed the moving average for the period of 200-days by -11.29% in comparison to the 20-day moving average, which settled at $77.81. In addition, Gilead Sciences, Inc. saw -13.20% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at GILD starting from Dickinson Andrew D, who sale 5,000 shares at the price of $80.00 back on Oct 17. After this action, Dickinson Andrew D now owns 104,003 shares of Gilead Sciences, Inc., valued at $400,017 using the latest closing price.
Parsey Merdad, the Chief Medical Officer of Gilead Sciences, Inc., sale 1,501 shares at $76.99 during a trade that took place back on Sep 12, which means that Parsey Merdad is holding 70,130 shares at $115,562 based on the most recent closing price.
Stock Fundamentals for GILD
Current profitability levels for the company are sitting at:
- +39.72 for the present operating margin
- +79.11 for the gross margin
The net margin for Gilead Sciences, Inc. stands at +16.95. The total capital return value is set at 22.70, while invested capital returns managed to touch 10.10. Equity return is now at value 27.08, with 9.41 for asset returns.
Based on Gilead Sciences, Inc. (GILD), the company’s capital structure generated 118.79 points at debt to equity in total, while total debt to capital is 54.29. Total debt to assets is 39.94, with long-term debt to equity ratio resting at 108.08. Finally, the long-term debt to capital ratio is 49.40.
When we switch over and look at the enterprise to sales, we see a ratio of 4.10, with the company’s debt to enterprise value settled at 0.20. The receivables turnover for the company is 5.84 and the total asset turnover is 0.41. The liquidity ratio also appears to be rather interesting for investors as it stands at 1.29.
Conclusion
In conclusion, Gilead Sciences, Inc. (GILD) has had a bad performance lately. Opinion on the stock among analysts is mixed, with some giving it a “buy” rating and others a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
